LT2632921T - 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazolo polimorfai ir druskos kaip pi3k inhibitoriai, skirti panaudoti pvz. kvėpavimo takų ligų gydymui - Google Patents

6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazolo polimorfai ir druskos kaip pi3k inhibitoriai, skirti panaudoti pvz. kvėpavimo takų ligų gydymui

Info

Publication number: LT2632921T
Authority: LT; Lithuania
Prior art keywords: oxazol; indazole; polymorphs; indol; methylethyl
Prior art date: 2010-10-27

Application number

LTEP11776738.4T

Other languages

English (en)

Inventor

Julie Nicole Hamblin

Paul Spencer Jones

Suzanne Elaine Keeling

Joelle Le

Nigel James Parr

Robert David Willacy

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-27

Filing date

2011-10-25

Publication date

2018-12-27

2011-10-25 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2018-12-27 Publication of LT2632921T publication Critical patent/LT2632921T/lt

Links

MCIDWGZGWVSZMK-UHFFFAOYSA-N 2-[6-(1h-indol-4-yl)-1h-indazol-4-yl]-5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazole Chemical class C1CN(C(C)C)CCN1CC1=CN=C(C=2C=3C=NNC=3C=C(C=2)C=2C=3C=CNC=3C=CC=2)O1 MCIDWGZGWVSZMK-UHFFFAOYSA-N 0.000 title 1
239000012828 PI3K inhibitor Substances 0.000 title 1
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
208000023504 respiratory system disease Diseases 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Hematology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

LTEP11776738.4T 2010-10-27 2011-10-25 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazolo polimorfai ir druskos kaip pi3k inhibitoriai, skirti panaudoti pvz. kvėpavimo takų ligų gydymui LT2632921T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1018124.6A GB201018124D0 (en)	2010-10-27	2010-10-27	Polymorphs and salts
PCT/EP2011/068604 WO2012055846A1 (en)	2010-10-27	2011-10-25	Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5- { [4-(1-methylethyl)-1-pi perazinyl] methyl} -1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders

Publications (1)

Publication Number	Publication Date
LT2632921T true LT2632921T (lt)	2018-12-27

Family

ID=43365584

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP11776738.4T LT2632921T (lt)	2010-10-27	2011-10-25	6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazolo polimorfai ir druskos kaip pi3k inhibitoriai, skirti panaudoti pvz. kvėpavimo takų ligų gydymui

Country Status (26)

Country	Link
US (1)	US8993576B2 (lt)
EP (2)	EP2632921B1 (lt)
JP (1)	JP5894603B2 (lt)
KR (1)	KR101774026B1 (lt)
CN (1)	CN103270037B (lt)
AU (1)	AU2011322649B2 (lt)
BR (1)	BR112013010126B1 (lt)
CA (1)	CA2814436C (lt)
CY (1)	CY1121248T1 (lt)
DK (1)	DK2632921T3 (lt)
EA (1)	EA022872B1 (lt)
ES (1)	ES2703716T3 (lt)
GB (1)	GB201018124D0 (lt)
HR (1)	HRP20182059T1 (lt)
HU (1)	HUE042754T2 (lt)
IL (1)	IL225704A (lt)
LT (1)	LT2632921T (lt)
MX (1)	MX347619B (lt)
PL (1)	PL2632921T3 (lt)
PT (1)	PT2632921T (lt)
RS (1)	RS58072B1 (lt)
SG (1)	SG189179A1 (lt)
SI (1)	SI2632921T1 (lt)
TR (1)	TR201819939T4 (lt)
WO (1)	WO2012055846A1 (lt)
ZA (1)	ZA201302480B (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8658635B2 (en)	2008-06-05	2014-02-25	Glaxosmithkline Intellectual Property Development Limited	Benzpyrazol derivatives as inhibitors of PI3 kinases
JP5502076B2 (ja)	2008-06-05	2014-05-28	グラクソグループリミテッド	新規化合物
ES2383246T3 (es)	2008-06-05	2012-06-19	Glaxo Group Limited	4-amino-indazoles
JP5656880B2 (ja)	2009-03-09	2015-01-21	グラクソグループリミテッドＧｌａｘｏＧｒｏｕｐＬｉｍｉｔｅｄ	Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
WO2010125082A1 (en)	2009-04-30	2010-11-04	Glaxo Group Limited	Oxazole substituted indazoles as pi3-kinase inhibitors
US9326987B2 (en) *	2010-09-08	2016-05-03	Glaxo Group Limited	Indazole derivatives for use in the treatment of influenza virus infection
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts
CA3128846C (en) *	2012-07-27	2025-05-06	Sato Pharmaceutical Co. Ltd.	COMPOSITE OF DIFLUOROMETHYLENE
US9737521B2 (en)	2012-11-08	2017-08-22	Rhizen Pharmaceuticals Sa	Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
KR20160062178A (ko)	2013-10-17	2016-06-01	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
JP2016537327A (ja) *	2013-10-17	2016-12-01	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	呼吸器疾患の治療のためのｐｉ３ｋ阻害剤
GB201509492D0 (en) *	2015-06-02	2015-07-15	Glaxosmithkline Ip Dev Ltd	Novel processes
JP7549306B2 (ja)	2016-07-22	2024-09-11	株式会社リピドームラボ	新規リン脂質およびその利用ならびにリン脂質分離測定法の開発

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9127376D0 (en)	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
HU225869B1 (en)	1992-04-02	2007-11-28	Smithkline Beecham Corp	Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
EP0957087B1 (en)	1994-06-15	2002-12-04	The Wellcome Foundation Limited	Intermediates useful in the preparation of enzyme inhibitors
AP791A (en)	1995-04-14	1999-12-17	Glaxo Wellcome Inc	Metered dose inhaler for albuterol.
MY117948A (en)	1997-01-13	2004-08-30	Glaxo Group Ltd	Nitride oxide synthase inhibitors.
DE19723722A1 (de)	1997-05-30	1998-12-10	Schering Ag	Nichtsteroidale Gestagene
TW533865U (en)	1997-06-10	2003-05-21	Glaxo Group Ltd	Dispenser for dispensing medicament and actuation indicating device
AU9281298A (en)	1997-10-01	1999-04-23	Kyowa Hakko Kogyo Co. Ltd.	Benzodioxole derivatives
US6506766B1 (en)	1998-02-13	2003-01-14	Abbott Laboratories	Glucocortiocoid-selective antinflammatory agents
JP2002506856A (ja)	1998-03-14	2002-03-05	ビイクグルデンロンベルクヒエーミツシエフアブリークゲゼルシヤフトミツトベシユレンクテルハフツング	フタラジノンｐｄｅｉｉｉ／ｉｖ阻害剤
GB9811599D0 (en)	1998-05-30	1998-07-29	Glaxo Group Ltd	Nitric oxide synthase inhibitors
US6119853A (en)	1998-12-18	2000-09-19	Glaxo Wellcome Inc.	Method and package for storing a pressurized container containing a drug
US6315112B1 (en)	1998-12-18	2001-11-13	Smithkline Beecham Corporation	Method and package for storing a pressurized container containing a drug
US6352152B1 (en)	1998-12-18	2002-03-05	Smithkline Beecham Corporation	Method and package for storing a pressurized container containing a drug
US6390291B1 (en)	1998-12-18	2002-05-21	Smithkline Beecham Corporation	Method and package for storing a pressurized container containing a drug
HK1043788A1 (zh)	1999-05-04	2002-09-27	American Home Products Corporation	四環黃體酮受體調節劑化合物及方法
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es)	1999-09-01	2002-07-30	Abbott Lab	Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en)	1999-12-08	2004-06-03	Advanced Medicine Inc	Beta 2-adrenergic receptor agonists.
WO2002012266A1 (en)	2000-08-05	2002-02-14	Glaxo Group Limited	17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
IL155093A0 (en)	2000-09-29	2003-10-31	Glaxo Group Ltd	Morpholin-acetamide derivatives for the treatment on inflammatory diseases
GB0031179D0 (en)	2000-12-21	2001-01-31	Glaxo Group Ltd	Nitric oxide synthase inhibitors
US6484903B2 (en)	2001-01-09	2002-11-26	Riverwood International Corporation	Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en)	2001-02-14	2001-03-28	Glaxo Group Ltd	Chemical compounds
WO2002067683A1 (en)	2001-02-26	2002-09-06	Merck & Co., Inc.	Hiv protease inhibitors supported on cation exchange resins for oral administration
EP1366025B1 (en)	2001-03-08	2007-06-27	Glaxo Group Limited	Agonists of beta-adrenoreceptors
JP4143413B2 (ja)	2001-03-22	2008-09-03	グラクソグループリミテッド	β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
WO2002083111A2 (en)	2001-04-16	2002-10-24	Tanabe Seiyaku Co., Ltd.	Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
PT1383786E (pt)	2001-04-30	2008-12-30	Glaxo Group Ltd	Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa
US20040248867A1 (en)	2001-06-12	2004-12-09	Keith Biggadike	Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
EP1407770B1 (en)	2001-06-26	2013-06-05	Takeda Pharmaceutical Company Limited	Tgf-beta superfamily production/secretion promoter
ES2438985T3 (es)	2001-09-14	2014-01-21	Glaxo Group Limited	Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
US6653323B2 (en)	2001-11-13	2003-11-25	Theravance, Inc.	Aryl aniline β2 adrenergic receptor agonists
WO2003051847A1 (en)	2001-12-19	2003-06-26	Smithkline Beecham P.L.C.	(1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
CA2472746A1 (en)	2002-01-14	2003-07-24	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
JP4745609B2 (ja)	2002-01-22	2011-08-10	ザリージェンツオブザユニバーシティオブカリフォルニア	グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用
TW200306819A (en)	2002-01-25	2003-12-01	Vertex Pharma	Indazole compounds useful as protein kinase inhibitors
GB0204719D0 (en)	2002-02-28	2002-04-17	Glaxo Group Ltd	Medicinal compounds
CA2477764A1 (en)	2002-03-26	2003-10-09	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
UA80120C2 (en)	2002-03-26	2007-08-27	Boehringer Ingelheim Pharma	Glucocorticoid mimetics, pharmaceutical composition based thereon
DE10215316C1 (de)	2002-04-02	2003-12-18	Schering Ag	Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
DE60335869D1 (de)	2002-04-11	2011-03-10	Merck Sharp & Dohme	1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
AU2003222841A1 (en)	2002-04-25	2003-11-10	Glaxo Group Limited	Phenethanolamine derivatives
US7186864B2 (en)	2002-05-29	2007-03-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en)	2002-06-06	2006-07-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2003233780A1 (en)	2002-06-27	2004-01-19	Novo Nordisk A/S	Novel glucagon antagonists/inverse agonists
SI1521733T1 (sl)	2002-07-08	2014-10-30	Pfizer Products Inc.	Modulatorji glukokortikoidnega receptorja
WO2004009017A2 (en)	2002-07-18	2004-01-29	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor and method
GB0217225D0 (en)	2002-07-25	2002-09-04	Glaxo Group Ltd	Medicinal compounds
AU2003264018A1 (en)	2002-08-09	2004-02-25	Astrazeneca Ab	Compounds having an activity at metabotropic glutamate receptors
MXPA05001592A (es)	2002-08-09	2005-05-05	Astrazeneca Ab	Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico.
IL166510A0 (en)	2002-08-09	2006-01-15	Nps Pharma Inc	1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
US20040224986A1 (en)	2002-08-16	2004-11-11	Bart De Corte	Piperidinyl targeting compounds that selectively bind integrins
CA2496175A1 (en)	2002-08-21	2004-03-04	Boehringer Ingelheim Pharmaceuticals, Inc.	Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0220730D0 (en)	2002-09-06	2002-10-16	Glaxo Group Ltd	Medicinal compounds
CN100387598C (zh)	2002-09-16	2008-05-14	葛兰素集团有限公司	吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途
GB0230045D0 (en)	2002-12-23	2003-01-29	Glaxo Group Ltd	Compounds
EP1542996A4 (en)	2002-09-20	2009-11-18	Merck & Co Inc	OCTAHYDRO-2H-NAPHTOc1,2-F INDOL-4-CARBONSUUREAMIDE DERIVATIVES AS SELECTIVE MODULATORS OF THE GLUCOCORTICOID RECEPTOR
GB0224084D0 (en)	2002-10-16	2002-11-27	Glaxo Group Ltd	Novel compounds
WO2004037807A2 (en)	2002-10-22	2004-05-06	Glaxo Group Limited	Medicinal arylethanolamine compounds
ATE390407T1 (de)	2002-10-28	2008-04-15	Glaxo Group Ltd	Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
GB0225030D0 (en)	2002-10-28	2002-12-04	Glaxo Group Ltd	Medicinal compounds
GB0225535D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
GB0225540D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
US7202257B2 (en)	2003-12-24	2007-04-10	Deciphera Pharmaceuticals, Llc	Anti-inflammatory medicaments
TWI328009B (en)	2003-05-21	2010-08-01	Glaxo Group Ltd	Quinoline derivatives as phosphodiesterase inhibitors
CA2528938A1 (en)	2003-06-13	2005-02-24	Zentaris Gmbh	Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
GB0316290D0 (en)	2003-07-11	2003-08-13	Glaxo Group Ltd	Novel compounds
US20050090529A1 (en)	2003-07-31	2005-04-28	Pfizer Inc	3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
GB0320197D0 (en) *	2003-08-28	2003-10-01	Novartis Ag	Organic compounds
AP2007004239A0 (en)	2003-10-14	2007-12-31	Glaxo Group Ltd	Muscarinic acetycholine receptor antagonists
EP2468729B1 (en)	2003-10-15	2013-12-25	Ube Industries, Ltd.	Novel indazole derivative
ES2388434T3 (es)	2003-11-03	2012-10-15	Glaxo Group Limited	Dispositivo de administración de fluido
PE20050489A1 (es)	2003-11-04	2005-09-02	Glaxo Group Ltd	Antagonistas de receptores de acetilcolina muscarinicos
US20070111995A1 (en)	2003-12-19	2007-05-17	Allen David G	Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
WO2005077368A2 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Compounds for the treatment of gastro-esophageal reflux disease
WO2005077373A2 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Treatment of gastro-esophageal reflux disease (gerd)
EP1713810B1 (en)	2004-02-04	2010-12-29	NeuroSearch A/S	Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
GB0405933D0 (en)	2004-03-16	2004-04-21	Glaxo Group Ltd	Compounds
US20080275078A1 (en)	2004-03-16	2008-11-06	Glaxo Group Limited	Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors
GB0405937D0 (en)	2004-03-16	2004-04-21	Glaxo Group Ltd	Compounds
PE20060259A1 (es)	2004-04-27	2006-03-25	Glaxo Group Ltd	Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
US8071624B2 (en)	2004-06-24	2011-12-06	Incyte Corporation	N-substituted piperidines and their use as pharmaceuticals
WO2006000401A1 (en)	2004-06-28	2006-01-05	Glaxo Group Limited	Substituted oxazines as glucocorticoid receptor modulators
WO2006000398A1 (en)	2004-06-28	2006-01-05	Glaxo Group Limited	2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
GB0418045D0 (en)	2004-08-12	2004-09-15	Glaxo Group Ltd	Compounds
MX2007004465A (es)	2004-10-19	2007-05-07	Hoffmann La Roche	Derivados de quinolina.
JP2008520700A (ja)	2004-11-18	2008-06-19	インサイト・コーポレイション	１１−βヒドロキシルステロイドデヒドロゲナーゼタイプＩの阻害剤およびその使用方法
WO2006060535A2 (en)	2004-11-30	2006-06-08	Plexxikon, Inc.	Indole derivatives for use as ppar active compounds
EP1841780B1 (en)	2005-01-10	2011-07-27	Glaxo Group Limited	Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
US20090124588A1 (en)	2005-01-10	2009-05-14	Glaxo Group Limited	Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
WO2006089076A2 (en)	2005-02-18	2006-08-24	Neurogen Corporation	Thiazole amides, imidazole amides and related analogues
US20060264433A1 (en)	2005-05-23	2006-11-23	Backes Bradley J	Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
WO2007011759A2 (en)	2005-07-15	2007-01-25	Kalypsys, Inc.	Inhibitors of mitotic kinesin
TW200800946A (en)	2005-08-15	2008-01-01	Astrazeneca Ab	Substituted piperazines as metabotropic glutamate receptor antagonists
EP1924265A4 (en)	2005-08-16	2010-06-02	Genzyme Corp	COMPOUNDS BINDING TO CHEMOKINE RECEPTORS
KR20090008217A (ko)	2006-03-10	2009-01-21	오노 야꾸힝 고교 가부시키가이샤	질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제
CA2647543A1 (en)	2006-03-29	2007-11-08	Foldrx Pharmaceuticals, Inc.	Inhibition of alpha-synuclein toxicity
WO2007114926A2 (en)	2006-04-04	2007-10-11	The Regents Of The University Of California	Kinase antagonists
GB0608820D0 (en)	2006-05-04	2006-06-14	Piramed Ltd	Pharmaceutical compounds
US8492378B2 (en)	2006-08-03	2013-07-23	Takeda Pharmaceutical Company Limited	GSK-3β inhibitor
WO2008020229A2 (en)	2006-08-17	2008-02-21	Astrazeneca Ab	Antibacterial pyrrolecarboxamides
TW200824687A (en)	2006-08-25	2008-06-16	Abbott Lab	Compounds that inhibit TRPV1 and uses thereof
US20100022541A1 (en)	2006-09-25	2010-01-28	Sonia Escaich	Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
WO2008037477A1 (en)	2006-09-29	2008-04-03	Novartis Ag	Pyrazolopyrimidines as p13k lipid kinase inhibitors
TWI405763B (zh)	2006-11-02	2013-08-21	Targacept Inc	菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
GB0701426D0 (en)	2007-01-25	2007-03-07	Univ Sheffield	Compounds and their use
US8450348B2 (en)	2007-02-21	2013-05-28	Forma Tm, Llc	Derivatives of squaric acid with anti-proliferative activity
JP2010116389A (ja)	2008-10-17	2010-05-27	Bayer Cropscience Ag	殺虫性アリールピロリジン類
US8648069B2 (en)	2007-06-08	2014-02-11	Abbvie Inc.	5-substituted indazoles as kinase inhibitors
EP2170884A2 (en)	2007-06-25	2010-04-07	Boehringer Ingelheim International GmbH	Chemical compounds
EP2183228B1 (en)	2007-07-26	2014-08-20	Vitae Pharmaceuticals, Inc.	CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1
AR071236A1 (es)	2008-05-01	2010-06-02	Vitae Pharmaceuticals Inc	Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
CL2009001059A1 (es)	2008-05-01	2010-11-12	Boehringer Ingelheim Int	Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras.
CA2723032A1 (en)	2008-05-01	2009-11-05	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009134387A1 (en)	2008-05-01	2009-11-05	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
ES2566339T3 (es)	2008-06-05	2016-04-12	Glaxo Group Limited	Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
ES2383246T3 (es)	2008-06-05	2012-06-19	Glaxo Group Limited	4-amino-indazoles
US8658635B2 (en)	2008-06-05	2014-02-25	Glaxosmithkline Intellectual Property Development Limited	Benzpyrazol derivatives as inhibitors of PI3 kinases
JP5502076B2 (ja) *	2008-06-05	2014-05-28	グラクソグループリミテッド	新規化合物
US10322469B2 (en)	2008-06-11	2019-06-18	Hamamatsu Photonics K.K.	Fusion bonding process for glass
WO2010011314A1 (en)	2008-07-25	2010-01-28	Boehringer Ingelheim International Gmbh	Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
WO2010068287A2 (en)	2008-12-11	2010-06-17	Angion Biomedica Corp.	Small molecule modulators of hepatocyte growth factor (scatter factor) activity
EP2403946A4 (en)	2009-03-04	2012-11-14		TREATMENT OF SIRTUIN 1 (SIRT1) -HANDLED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST SIRT 1
JP5656880B2 (ja) *	2009-03-09	2015-01-21	グラクソグループリミテッドＧｌａｘｏＧｒｏｕｐＬｉｍｉｔｅｄ	Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
US8343959B2 (en)	2009-04-30	2013-01-01	Abbott Gmbh & Co. Kg	N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
KR20120061771A (ko)	2009-04-30	2012-06-13	비타이 파마슈티컬즈, 인코포레이티드	11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
MX2011011520A (es)	2009-04-30	2012-06-19	Abbott Gmbh & Co Kg	Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfon amida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
EP2424838A1 (en)	2009-04-30	2012-03-07	Bayer CropScience AG	Pesticidal arylpyrrolidines
UA109255C2 (ru)	2009-04-30	2015-08-10	Берінгер Інгельхайм Інтернешнл Гмбх	Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
WO2010125082A1 (en) *	2009-04-30	2010-11-04	Glaxo Group Limited	Oxazole substituted indazoles as pi3-kinase inhibitors
US20120245171A1 (en)	2009-12-03	2012-09-27	Glaxo Group Limited	Benzpyrazole derivatives as inhibitors of pi3 kinases
EP2507226A1 (en)	2009-12-03	2012-10-10	Glaxo Group Limited	Novel compounds
EP2507231A1 (en)	2009-12-03	2012-10-10	Glaxo Group Limited	Indazole derivatives as pi 3 - kinase inhibitors
US9326987B2 (en) *	2010-09-08	2016-05-03	Glaxo Group Limited	Indazole derivatives for use in the treatment of influenza virus infection
RS54286B1 (sr)	2010-09-08	2016-02-29	Glaxosmithkline Intellectual Property Development Limited	Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts

2010
- 2010-10-27 GB GBGB1018124.6A patent/GB201018124D0/en not_active Ceased
2011
- 2011-10-25 PL PL11776738T patent/PL2632921T3/pl unknown
- 2011-10-25 AU AU2011322649A patent/AU2011322649B2/en not_active Ceased
- 2011-10-25 CA CA2814436A patent/CA2814436C/en active Active
- 2011-10-25 EP EP11776738.4A patent/EP2632921B1/en active Active
- 2011-10-25 SI SI201131625T patent/SI2632921T1/sl unknown
- 2011-10-25 SG SG2013023825A patent/SG189179A1/en unknown
- 2011-10-25 EP EP18199476.5A patent/EP3447055A1/en not_active Withdrawn
- 2011-10-25 BR BR112013010126-1A patent/BR112013010126B1/pt active IP Right Grant
- 2011-10-25 CN CN201180062847.7A patent/CN103270037B/zh active Active
- 2011-10-25 LT LTEP11776738.4T patent/LT2632921T/lt unknown
- 2011-10-25 ES ES11776738T patent/ES2703716T3/es active Active
- 2011-10-25 EA EA201390457A patent/EA022872B1/ru not_active IP Right Cessation
- 2011-10-25 DK DK11776738.4T patent/DK2632921T3/en active
- 2011-10-25 RS RS20181547A patent/RS58072B1/sr unknown
- 2011-10-25 MX MX2013004783A patent/MX347619B/es active IP Right Grant
- 2011-10-25 KR KR1020137013540A patent/KR101774026B1/ko not_active Expired - Fee Related
- 2011-10-25 US US13/879,667 patent/US8993576B2/en active Active
- 2011-10-25 PT PT11776738T patent/PT2632921T/pt unknown
- 2011-10-25 HR HRP20182059TT patent/HRP20182059T1/hr unknown
- 2011-10-25 HU HUE11776738A patent/HUE042754T2/hu unknown
- 2011-10-25 JP JP2013535398A patent/JP5894603B2/ja not_active Expired - Fee Related
- 2011-10-25 TR TR2018/19939T patent/TR201819939T4/tr unknown
- 2011-10-25 WO PCT/EP2011/068604 patent/WO2012055846A1/en not_active Ceased
2013
- 2013-04-05 ZA ZA2013/02480A patent/ZA201302480B/en unknown
- 2013-04-11 IL IL225704A patent/IL225704A/en active IP Right Grant
2018
- 2018-12-28 CY CY20181101406T patent/CY1121248T1/el unknown

Also Published As

Publication number	Publication date
EA201390457A1 (ru)	2013-11-29
KR101774026B1 (ko)	2017-09-01
MX347619B (es)	2017-05-04
RS58072B1 (sr)	2019-02-28
HUE042754T2 (hu)	2019-07-29
US20130203772A1 (en)	2013-08-08
CY1121248T1 (el)	2020-05-29
SI2632921T1 (sl)	2019-01-31
AU2011322649A1 (en)	2013-05-02
EP3447055A1 (en)	2019-02-27
PT2632921T (pt)	2019-01-17
GB201018124D0 (en)	2010-12-08
KR20130133197A (ko)	2013-12-06
HRP20182059T1 (hr)	2019-02-08
EP2632921A1 (en)	2013-09-04
TR201819939T4 (tr)	2019-02-21
JP2013540790A (ja)	2013-11-07
ZA201302480B (en)	2016-01-27
IL225704A0 (en)	2013-06-27
CN103270037B (zh)	2015-10-21
MX2013004783A (es)	2013-06-03
CN103270037A (zh)	2013-08-28
AU2011322649B2 (en)	2015-11-19
BR112013010126B1 (pt)	2021-05-25
CA2814436A1 (en)	2012-05-03
DK2632921T3 (en)	2019-01-21
SG189179A1 (en)	2013-05-31
CA2814436C (en)	2019-03-19
BR112013010126A8 (pt)	2018-01-23
IL225704A (en)	2015-11-30
PL2632921T3 (pl)	2019-04-30
US8993576B2 (en)	2015-03-31
WO2012055846A1 (en)	2012-05-03
EP2632921B1 (en)	2018-10-17
JP5894603B2 (ja)	2016-03-30
ES2703716T3 (es)	2019-03-12
EA022872B1 (ru)	2016-03-31
BR112013010126A2 (pt)	2016-09-06

Publication	Publication Date	Title
IL225704A (en)	2015-11-30	Polymorphs and salts of 6– (1 h– indole – 4 – ram) –4– (5 - {[4– (1-methylethyl) –1 – piperazine] methyl} –1,3 – oxazole – 2 – ram) –1 h- Indazole as pi3k inhibitors for use in treating respiratory problems
LTC2331537I2 (lt)	2022-01-10	1-((5-heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamido dariniai, kaip fosfatidilinozitolio 3-kinazės (pi3k) inhibitoriai, naudingi proliferacinių ligų gydyme
IL208350A0 (en)	2010-12-30	Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
IL220155B (en)	2019-05-30	History of 2, 4-(phenyl-amine-)di-converted pyrimidines for use as kinase inhibitors
PL2321295T3 (pl)	2012-06-29	Pochodne 4-(pirydyn-4-ylo)-1H-[1,3,5]triazyn -2-onu jako inhibitory GSK2-beta do leczenia chorób degeneracyjnych
PT2900637T (pt)	2017-11-15	Derivados de amida de pirimidina, piridina e pirazina substituídos com tiazole ou imidazole e compostos relacionados como inibidores de abl1, abl2 e bcr-abl1 para tratamento do cancro, infecções virais específicas e disturbios do snc específicos
PL2947072T3 (pl)	2017-05-31	1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
IL223181A0 (en)	2013-02-03	The use of inhibitors of bruton's tyrosine kinase (btk)
IL219914A0 (en)	2012-07-31	Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
NZ599513A (en)	2013-11-29	Compounds for the treatment of dyslipidemia and related diseases
PL2475368T3 (pl)	2015-05-29	N-(4-((3-(2-amino-4-pirymidynylo)-2-pirydynylo)oksy)fenylo)-4-(4-metylo-2-tienylo)-1-ftalazynoamina do stosowania w leczeniu raka opornego na czynniki antymitotyczne
ZA201008886B (en)	2011-08-31	Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
IL216149A (en)	2016-02-29	Heterocyclic phenoxymethyl compounds, their pharmaceutical preparations and their use in the preparation of drugs for the treatment of central nervous system disorders
NO20084892L (no)	2009-01-06	C-kit kinase inhibitor for anvendelse i terapeutisk behandling av gastrointestinal stromaltumor eller mastocytose.
ZA201007060B (en)	2011-06-29	Pyrazinone derivatives as insulin secretion stimulators,methods for obtaining them and use thereof for the treatment of diabetes
NZ603859A (en)	2014-07-25	Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferative disorders
SMT201800688T1 (it)	2019-01-11	Polimorfi e sali di 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-ossazol-2-il)-1h-indazolo come inibitori di pi3k per uso nel trattamento ad esempio di disordini respiratori”
ZA201103134B (en)	2012-01-25	(pyrrolidin-2 yl) phenyl derivatives for use in the treatment of pain
NZ722945A (en)	2018-02-23	Apoptosis signal-regulating kinase inhibitor
HK1193102A (en)	2014-09-12	Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide solubilized using organic acids
DK2271342T3 (da)	2012-10-29	Anvendelse af nicotinamid til behandling af sommereksem hos heste
HK1149932A (en)	2011-10-21	Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease